John Field

List of Publications by Year in Descending Order

348 papers	18,598 citations	69 h-index	124 g-index
393 ext. papers	21,781 ext. citations	6.9 avg, IF	6.12 L-index

#	Paper	IF	Citations
348	Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk.. *Human Molecular Genetics*, **2022**,	5.6	1
347	Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer.. *European Journal of Medical Research*, **2022**, 27, 14	4.8	
346	Iam hiQ-a novel pair of accuracy indices for imputed genotypes.. *BMC Bioinformatics*, **2022**, 23, 50	3.6	0
345	Understanding the lung cancer mortality reductions produced by low-dose CT screening-AuthorsP reply.. *Lancet Regional Health - Europe, The*, **2022**, 12, 100259		
344	Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. *PLoS Genetics*, **2021**, 17, e1009254	6	2
343	A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?". *Lung Cancer*, **2021**, 154, 225-226	5.9	
342	A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. *Npj Precision Oncology*, **2021**, 5, 39	9.8	1
341	Application of two job indices for general occupational demands in a pooled analysis of case-control studies on lung cancer. *Scandinavian Journal of Work, Environment and Health*, **2021**, 47, 475-481	4.3	
340	Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives. *Nature Reviews Clinical Oncology*, **2021**, 18, 135-151	19.4	62
339	Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer. *Genetic Epidemiology*, **2021**, 45, 99-114	2.6	2
338	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. *Lung Cancer*, **2021**, 152, 58-65	5.9	6
337	Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. *Thorax*, **2021**, 76, 161-168	7.3	5
336	Causal relationships between body mass index, smoking and lung cancer: Univariable and multivariable Mendelian randomization. *International Journal of Cancer*, **2021**, 148, 1077-1086	7.5	18
335	Comprehensive functional annotation of susceptibility variants identifies genetic heterogeneity between lung adenocarcinoma and squamous cell carcinoma. *Frontiers of Medicine*, **2021**, 15, 275-291	12	6
334	Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model. *Cancer Research*, **2021**, 81, 1607-1615	10.1	6
333	Rare deleterious germline variants and risk of lung cancer. *Npj Precision Oncology*, **2021**, 5, 12	9.8	0
332	Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. *Lancet Regional Health - Europe, The*, **2021**, 10, 100179		13

331	Analysis of the baseline performance of five UK lung cancer screening programmes. *Lung Cancer*, **2021**, 161, 136-140	5.9	5
330	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. *Translational Lung Cancer Research*, **2020**, 9, 269-279	4.4	25
329	Diesel Engine Exhaust Exposure, Smoking, and Lung Cancer Subtype Risks. A Pooled Exposure-Response Analysis of 14 Case-Control Studies. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 402-411	10.2	12
328	Respirable Crystalline Silica Exposure, Smoking, and Lung Cancer Subtype Risks. A Pooled Analysis of Case-Control Studies. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 412-421	10.2	11
327	Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nature Communications*, **2020**, 11, 2220	17.4	6
326	The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. *JCO Clinical Cancer Informatics*, **2020**, 4, 89-99	5.2	6
325	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. *Cancers*, **2020**, 12,	6.6	18
324	Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis. *British Journal of Cancer*, **2020**, 122, 1050-1058	8.7	38
323	Lung cancer: a potential role for dentists. *British Dental Journal*, **2020**, 228, 413-414	1.2	3
322	Development and validation of a multivariable risk prediction model for head and neck cancer using the UK Biobank. *International Journal of Oncology*, **2020**, 57, 1192-1202	4.4	
321	Transcriptome-wide association study reveals candidate causal genes for lung cancer. *International Journal of Cancer*, **2020**, 146, 1862-1878	7.5	8
320	Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk. *International Journal of Cancer*, **2020**, 146, 2855-2864	7.5	2
319	Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. *Nature Communications*, **2020**, 11, 27	17.4	7
318	Genetic Determinants of Lung Cancer Prognosis in Never Smokers: A Pooled Analysis in the International Lung Cancer Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1983-1992	4	5
317	Association Analysis of Driver Gene-Related Genetic Variants Identified Novel Lung Cancer Susceptibility Loci with 20,871 Lung Cancer Cases and 15,971 Controls. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1423-1429	4	2
316	Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 935-942	4	12
315	Presentation of lung cancer in primary care. *Npj Primary Care Respiratory Medicine*, **2019**, 29, 21	3.2	12
314	Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. *Lung Cancer*, **2019**, 134, 79-84	5.9	49

313	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. *Oncotarget*, **2019**, 10, 1760-1774	3.3	12
312	Implementation planning for lung cancer screening in China. *Precision Clinical Medicine*, **2019**, 2, 13-44	6.7	17
311	Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. *Thorax*, **2019**, 74, 761-767	7.3	15
310	Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. *Nature Communications*, **2019**, 10, 3407	17.4	64
309	Lung Cancer Risk in Never-Smokers of European Descent is Associated With Genetic Variation in the 515.33 TERT-CLPTM1Ll Region. *Journal of Thoracic Oncology*, **2019**, 14, 1360-1369	8.9	12
308	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. *Journal of Thoracic Oncology*, **2019**, 14, 1594-1607	8.9	34
307	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1228-1237	4	5
306	Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme. *Lung Cancer*, **2019**, 134, 66-71	5.9	21
305	Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. *European Journal of Radiology*, **2019**, 120, 108646	4.7	9
304	Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. *BMC Cancer*, **2019**, 19, 1068	4.8	11
303	Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion. *ESMO Open*, **2019**, 4, e000577	6	18
302	Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges. *Journal of Thoracic Oncology*, **2019**, 14, 343-357	8.9	142
301	Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. *Carcinogenesis*, **2019**, 40, 432-440	4.6	3
300	Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. *International Journal of Epidemiology*, **2019**, 48, 751-766	7.8	14
299	Low-dose CT for lung cancer screening - AuthorsPreply. *Lancet Oncology, The*, **2018**, 19, e135-e136	21.7	3
298	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. *Carcinogenesis*, **2018**, 39, 336-346	4.6	11
297	EUPS-argues that lung cancer screening should be implemented in 18 months. *British Journal of Radiology*, **2018**, 91, 20180243	3.4	3
296	Utilizing Lung Cancer Risk Prediction Models to Promote Smoking Cessation: Two Randomized Controlled Trials. *American Journal of Health Promotion*, **2018**, 32, 1196-1205	2.5	6

295	The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. *European Radiology*, **2018**, 28, 226-234	8	11
294	Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 1483-1495	8.9	12
293	Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. *Nature Communications*, **2018**, 9, 3221	17.4	29
292	Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. *EBioMedicine*, **2018**, 32, 93-101	8.8	23
291	Lung cancer and socioeconomic status in a pooled analysis of case-control studies. *PLoS ONE*, **2018**, 13, e0192999	3.7	54
290	Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. *Nature Communications*, **2018**, 9, 3927	17.4	24
289	Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. *International Archives of Occupational and Environmental Health*, **2018**, 91, 937-950	3.2	17
288	Aurora B expression modulates paclitaxel response in non-small cell lung cancer. *British Journal of Cancer*, **2017**, 116, 592-599	8.7	26
287	COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer. *Journal of Cancer Research and Clinical Oncology*, **2017**, 143, 1133-1141	4.9	37
286	The role of screening expectations in modifying short-term psychological responses to low-dose computed tomography lung cancer screening among high-risk individuals. *Patient Education and Counseling*, **2017**, 100, 1572-1579	3.1	5
285	Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung Cancer. *Scientific Reports*, **2017**, 7, 42190	4.9	35
284	Association between smoking and health outcomes in an economically deprived population: the Liverpool Lung Project. *Journal of Epidemiology and Community Health*, **2017**, 71, 806-810	5.1	6
283	Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. *Clinical Chemistry*, **2017**, 63, 1288-1296	5.5	60
282	mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. *Oncology Letters*, **2017**, 13, 4463-4468	2.6	18
281	Exposure-Response Analyses of Asbestos and Lung Cancer Subtypes in a Pooled Analysis of Case-Control Studies. *Epidemiology*, **2017**, 28, 288-299	3.1	41
280	Scientific Advances in Thoracic Oncology 2016. *Journal of Thoracic Oncology*, **2017**, 12, 1183-1209	8.9	29
279	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. *Nature Genetics*, **2017**, 49, 1126-1132	36.3	246
278	Age at menopause and hormone replacement therapy as risk factors for head and neck and oesophageal cancer (Review). *Oncology Reports*, **2017**, 38, 1915-1922	3.5	6

277	Common Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium. *Clinical Cancer Research*, **2017**, 23, 7550-7557	12.9	4
276	Risk assessment in relation to the detection of small pulmonary nodules. *Translational Lung Cancer Research*, **2017**, 6, 35-41	4.4	8
275	Pleiotropy of genetic variants on obesity and smoking phenotypes: Results from the Oncoarray Project of The International Lung Cancer Consortium. *PLoS ONE*, **2017**, 12, e0185660	3.7	7
274	EU Policy on Lung Cancer CT Screening 2017. *Biomedicine Hub*, **2017**, 2, 154-161	1.3	4
273	Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. *Thorax*, **2017**, 72, 912-918	7.3	56
272	European position statement on lung cancer screening. *Lancet Oncology, The*, **2017**, 18, e754-e766	21.7	279
271	Management of proliferative verrucous leukoplakia: Justification for a conservative approach. *Head and Neck*, **2017**, 39, 1997-2003	4.2	23
270	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
269	Abstract 4220: Liverpool healthy lung project: a primary care initiative to identify hard to reach individuals with a high risk of developing lung cancer **2017**,		2
268	Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. *PLoS ONE*, **2017**, 12, e0177875	3.7	56
267	Occupational prestige, social mobility and the association with lung cancer in men. *BMC Cancer*, **2016**, 16, 395	4.8	12
266	The causal relevance of body mass index in different histological types of lung cancer: A Mendelian randomization study. *Scientific Reports*, **2016**, 6, 31121	4.9	23
265	Perceptions towards electronic cigarettes for smoking cessation among Stop Smoking Service users. *British Journal of Health Psychology*, **2016**, 21, 421-33	8.3	19
264	Response to Oral epithelial dysplasia in oral submucous fibrosis: A challenge. *Oral Oncology*, **2016**, 54, e20	4.4	
263	CT screening for lung cancer: Is the evidence strong enough?. *Lung Cancer*, **2016**, 91, 29-35	5.9	31
262	Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. *Carcinogenesis*, **2016**, 37, 96-105	4.6	27
261	Lung cancer CT screening: is annual screening necessary?. *Lancet Oncology, The*, **2016**, 17, 543-4	21.7	12
260	UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax*, **2016**, 71, 161-70	7.3	163

259	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. *Health Technology Assessment*, **2016**, 20, 1-146	4.4	124
258	Computed Tomography Characterisation of Lung Nodules and Management of Incidentally Detected Nodules. *Medical Radiology*, **2016**, 183-193	0.2	
257	Electronic cigarettes: a survey of perceived patient use and attitudes among members of the British thoracic oncology group. *Respiratory Research*, **2016**, 17, 55	7.3	15
256	Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. *Thorax*, **2016**, 71, 996-1005	7.3	48
255	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. *International Journal of Oncology*, **2016**, 49, 361-70	4.4	15
254	Lung Cancer Among Firefighters: Smoking-Adjusted Risk Estimates in a Pooled Analysis of Case-Control Studies. *Journal of Occupational and Environmental Medicine*, **2016**, 58, 1137-1143	2	11
253	Implementation planning for lung cancer screening: five major challenges. *Lancet Respiratory Medicine,the*, **2016**, 4, 685-687	35.1	9
252	P1.04: Defining the Genetic Architecture of Lung Cancer Etiology. *Journal of Thoracic Oncology*, **2016**, 11, S182	8.9	5
251	Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. *British Journal of Radiology*, **2016**, 89, 20160301	3.4	12
250	Comprehensive genomic profiles of small cell lung cancer. *Nature*, **2015**, 524, 47-53	50.4	1061
249	Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project. *Oncology Letters*, **2015**, 9, 1902-1906	2.6	12
248	LLPi: Liverpool Lung Project Risk Prediction Model for Lung Cancer Incidence. *Cancer Prevention Research*, **2015**, 8, 570-5	3.2	40
247	Lung cancer risk among cooks when accounting for tobacco smoking: a pooled analysis of case-control studies from Europe, Canada, New Zealand, and China. *Journal of Occupational and Environmental Medicine*, **2015**, 57, 202-9	2	8
246	Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. *Carcinogenesis*, **2015**, 36, 1314-26	4.6	8
245	Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. *EBioMedicine*, **2015**, 2, 1677-85	8.8	29
244	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. *Human Molecular Genetics*, **2015**, 24, 7406-20	5.6	11
243	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	47
242	Electronic cigarette use and risk perception in a Stop Smoking Service in England. *Addiction Research and Theory*, **2015**, 23, 336-342	2.6	10

241	A concordance index for matched case-control studies with applications in cancer risk. *Statistics in Medicine*, **2015**, 34, 396-405	2.3	18
240	Lung cancer risk among bricklayers in a pooled analysis of case-control studies. *International Journal of Cancer*, **2015**, 136, 360-71	7.5	22
239	Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. *BMJ Open*, **2015**, 5, e008254	3	94
238	Trends and regional variation in the incidence of head and neck cancers in England: 2002 to 2011. *International Journal of Oncology*, **2015**, 47, 204-10	4.4	24
237	Lung cancer trend in England for the period of 2002 to 2011 and projections of future burden until 2020. *International Journal of Oncology*, **2015**, 47, 739-46	4.4	6
236	Lung cancer screening: identifying the high risk cohort. *Journal of Thoracic Disease*, **2015**, 7, S156-62	2.6	18
235	Lung cancer among coal miners, ore miners and quarrymen: smoking-adjusted risk estimates from the synergy pooled analysis of case-control studies. *Scandinavian Journal of Work, Environment and Health*, **2015**, 41, 467-77	4.3	26
234	Lung Cancer Screening **2015**, 1-11		
233	Effect modification of the association of cumulative exposure and cancer risk by intensity of exposure and time since exposure cessation: a flexible method applied to cigarette smoking and lung cancer in the SYNERGY Study. *American Journal of Epidemiology*, **2014**, 179, 290-8	3.8	33
232	MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model. *International Journal of Health Promotion and Education*, **2014**, 52, 144-152	0.8	4
231	Unique volatolomic signatures of TP53 and KRAS in lung cells. *British Journal of Cancer*, **2014**, 111, 1213-21	8.7	34
230	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nature Communications*, **2014**, 5, 3518	17.4	173
229	Perspective: The screening imperative. *Nature*, **2014**, 513, S7	50.4	13
228	Factors associated with dropout in a lung cancer high-risk cohort--the Liverpool lung project. *International Journal of Oncology*, **2014**, 44, 2146-52	4.4	5
227	Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. *British Journal of Cancer*, **2014**, 110, 1834-40	8.7	23
226	Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia. *Journal of the National Cancer Institute*, **2014**, 106, dju061	9.7	28
225	Is previous respiratory disease a risk factor for lung cancer?. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 549-59	10.2	73
224	Education and lung cancer among never smokers. *Epidemiology*, **2014**, 25, 934-5	3.1	3

223	Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO). *International Journal of Cancer*, **2014**, 135, 1918-30	7.5	69
222	A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. *Annals of Oncology*, **2014**, 25, 781-791	10.3	12
221	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. *Journal of Thoracic Oncology*, **2014**, 9, 141-3	8.9	20
220	E-cigarettes and cancer patients. *Journal of Thoracic Oncology*, **2014**, 9, 438-41	8.9	39
219	The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. *Cancer Prevention Research*, **2014**, 7, 362-71	3.2	84
218	Epigenetic biomarkers in lung cancer. *Cancer Letters*, **2014**, 342, 200-12	9.9	103
217	Abstract 1531: Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets **2014**,		11
216	The role of DNA methylation as biomarkers in the clinical management of lung cancer. *Expert Review of Respiratory Medicine*, **2013**, 7, 363-83	3.8	31
215	A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. *British Journal of Cancer*, **2013**, 109, 2404-11	8.7	22
214	A prognostic DNA methylation signature for stage I non-small-cell lung cancer. *Journal of Clinical Oncology*, **2013**, 31, 4140-7	2.2	210
213	Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: rationale for monitoring premalignant oral lesions in a multidisciplinary clinic. *British Journal of Oral and Maxillofacial Surgery*, **2013**, 51, 594-9	1.4	42
212	A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. *BMC Genomics*, **2013**, 14 Suppl 6, S5	4.5	9
211	Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer. *BMC Systems Biology*, **2013**, 7 Suppl 5, S1	3.5	56
210	Prospects for population screening and diagnosis of lung cancer. *Lancet, The*, **2013**, 382, 732-41	40	99
209	The contribution of risk prediction models to early detection of lung cancer. *Journal of Surgical Oncology*, **2013**, 108, 304-11	2.8	19
208	Cytoglobin has bimodal: tumour suppressor and oncogene functions in lung cancer cell lines. *Human Molecular Genetics*, **2013**, 22, 3207-17	5.6	30
207	CT screening for lung cancer: countdown to implementation. *Lancet Oncology, The*, **2013**, 14, e591-600	21.7	49
206	Improving care for patients with lung cancer in the UK. *Thorax*, **2013**, 68, 1181-5	7.3	9

205	AuthorsPresponse. *Thorax*, **2013**, 68, 105	7.3	
204	Lung cancer risk among bakers, pastry cooks and confectionary makers: the SYNERGY study. *Occupational and Environmental Medicine*, **2013**, 70, 810-4	2.1	10
203	European randomized lung cancer screening trials: Post NLST. *Journal of Surgical Oncology*, **2013**, 108, 280-6	2.8	75
202	TPL2 kinase is a suppressor of lung carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1470-9	11.5	39
201	In response. Predictive accuracy of the Liverpool Lung Project risk model. *Annals of Internal Medicine*, **2013**, 158, 568-9	8	2
200	Conference Scene: 11th Annual British Thoracic Oncology Group Conference 2013. *Lung Cancer Management*, **2013**, 2, 103-105	2.6	
199	Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 25-33	1.5	89
198	The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 33-8	1.5	438
197	Early detection of lung cancer with low-dose computed tomography: an update on recently presented data. *Lung Cancer Management*, **2012**, 1, 189-194	2.6	
196	Progressive lung cancer determined by expression profiling and transcriptional regulation. *International Journal of Oncology*, **2012**, 41, 242-52	4.4	5
195	DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. *Cancer Research*, **2012**, 72, 5692-701	10.1	103
194	Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. *American Journal of Epidemiology*, **2012**, 176, 573-85	3.8	123
193	Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. *European Journal of Cancer*, **2012**, 48, 1957-68	7.5	98
192	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature Genetics*, **2012**, 44, 1104-10	36.3	919
191	The clinical determinants of malignant transformation in oral epithelial dysplasia. *Oral Oncology*, **2012**, 48, 969-976	4.4	87
190	Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. *Lung Cancer*, **2012**, 75, 156-60	5.9	15
189	Development and performance evaluation of a CE-IVD for measuring SHOX2 DNA methylation in bronchial aspirates for the diagnosis of lung cancer. *Lung Cancer*, **2012**, 77, S22	5.9	2
188	RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. *American Journal of Human Genetics*, **2012**, 90, 340-6	11	127

187	Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. *International Journal of Oncology*, **2012**, 40, 825-32	4.4	51
186	Informed conditioning on clinical covariates increases power in case-control association studies. *PLoS Genetics*, **2012**, 8, e1003032	6	58
185	Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Human Molecular Genetics*, **2012**, 21, 4980-95	5.6	159
184	Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. *European Respiratory Journal*, **2012**, 40, 177-84	13.6	73
183	DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. *Diagnostic Molecular Pathology*, **2012**, 21, 93-104		73
182	Measurement methods and algorithms for the management of solid nodules. *Journal of Thoracic Imaging*, **2012**, 27, 230-9	5.6	18
181	Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. *Carcinogenesis*, **2012**, 33, 587-97	4.6	54
180	Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer Consortium. *Carcinogenesis*, **2012**, 33, 1059-64	4.6	33
179	Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. *Journal of Clinical Oncology*, **2012**, 30, 1129-36	2.2	58
178	Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. *Annals of Internal Medicine*, **2012**, 157, 242-50	8	119
177	Neuroglobin and myoglobin in non-small cell lung cancer: expression, regulation and prognosis. *Lung Cancer*, **2011**, 74, 411-8	5.9	43
176	Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer. *Cancer Letters*, **2011**, 300, 79-86	9.9	40
175	A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. *PLoS Genetics*, **2011**, 7, e1001333	6	136
174	UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. *Thorax*, **2011**, 66, 308-13	7.3	146
173	Cytoglobin: biochemical, functional and clinical perspective of the newest member of the globin family. *Cellular and Molecular Life Sciences*, **2011**, 68, 3869-83	10.3	59
172	UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. *Cancer*, **2011**, 117, 1027-37	6.4	79
171	Lung cancer risk prediction to select smokers for screening CT--a model based on the Italian COSMOS trial. *Cancer Prevention Research*, **2011**, 4, 1778-89	3.2	91
170	SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. *Journal of Thoracic Oncology*, **2011**, 6, 1632-8	8.9	173

169	CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST report. *Thorax*, **2011**, 66, 736-7	7.3	25
168	Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. *FEBS Journal*, **2010**, 277, 3014-27	5.7	15
167	Comparison of discriminatory power and accuracy of three lung cancer risk models. *British Journal of Cancer*, **2010**, 103, 423-9	8.7	53
166	Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project. *Cancer Prevention Research*, **2010**, 3, 664-9	3.2	47
165	Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. *International Journal of Epidemiology*, **2010**, 39, 563-77	7.8	110
164	Detection of DNA methylation changes in body fluids. *Advances in Genetics*, **2010**, 71, 177-207	3.3	4
163	DNA methylation epigenotypes in breast cancer molecular subtypes. *Breast Cancer Research*, **2010**, 12, R77	8.3	141
162	Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. *Human Immunology*, **2010**, 71, 976-81	2.3	42
161	Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. *International Journal of Oncology*, **2010**, 37, 455-61	4.4	3
160	SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. *BMC Cancer*, **2010**, 10, 600	4.8	130
159	The potential for using risk models in future lung cancer screening trials. *F1000 Medicine Reports*, **2010**, 2,		10
158	Cytoglobin is upregulated by tumour hypoxia and silenced by promoter hypermethylation in head and neck cancer. *British Journal of Cancer*, **2009**, 101, 139-44	8.7	48
157	Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 179, 396-401	10.2	55
156	A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. *Cancer Research*, **2009**, 69, 5210-7	10.1	37
155	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. *European Respiratory Journal*, **2009**, 34, 1477-86	13.6	14
154	Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. *International Journal of Cancer*, **2009**, 124, 81-7	7.5	225
153	Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. *Proteomics*, **2009**, 9, 74-86	4.8	41
152	Reactors: A data-oriented synchronous/asynchronous programming model for distributed applications. *Theoretical Computer Science*, **2009**, 410, 168-201	1.1	9

151	A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. *American Journal of Human Genetics*, **2009**, 85, 679-91	11	442
150	Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. *European Journal of Cancer*, **2009**, 45, 3047-53	7.5	13
149	Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. *Expert Review of Anticancer Therapy*, **2009**, 9, 1467-72	3.5	8
148	A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature*, **2008**, 452, 633-7	50.4	1003
147	The LLP risk model: an individual risk prediction model for lung cancer. *British Journal of Cancer*, **2008**, 98, 270-6	8.7	304
146	Lung cancer screening: the way forward. *British Journal of Cancer*, **2008**, 99, 557-62	8.7	42
145	Lung cancer susceptibility locus at 5p15.33. *Nature Genetics*, **2008**, 40, 1404-6	36.3	466
144	The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression. *JAMA Otolaryngology*, **2008**, 134, 251-6		34
143	Lung cancer risk models come of age. *Cancer Prevention Research*, **2008**, 1, 226-8	3.2	13
142	Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. *Cancer Research*, **2008**, 68, 7448-56	10.1	79
141	p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2174-9	4	74
140	International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 3081-9	4	86
139	Generation of a non-small cell lung cancer transcriptome microarray. *BMC Medical Genomics*, **2008**, 1, 20	3.7	18
138	Environmental and Genetic Risk Factors of Lung Cancer **2007**, 67-100		3
137	Lung cancer risk prediction: a tool for early detection. *International Journal of Cancer*, **2007**, 120, 1-6	7.5	79
136	CpG island methylation phenotype (CIMP) in oral cancer: associated with a marked inflammatory response and less aggressive tumour biology. *Oral Oncology*, **2007**, 43, 878-86	4.4	40
135	Seizure 6-like (SEZ6L) gene and risk for lung cancer. *Cancer Research*, **2007**, 67, 8406-11	10.1	22
134	M09-03: Biomarkers and risk models for stratification of high risk individuals. *Journal of Thoracic Oncology*, **2007**, 2, S176	8.9	1

133	Occupational exposure to crystalline silica and risk of lung cancer: a multicenter case-control study in Europe. *Epidemiology*, **2007**, 18, 36-43	3.1	79
132	Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. *British Journal of Oral and Maxillofacial Surgery*, **2007**, 45, 617-22	1.4	48
131	Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. *International Journal of Cancer*, **2006**, 119, 2546-56	7.5	64
130	Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. *Nucleic Acids Research*, **2006**, 34, e78	20.1	71
129	Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. *Human Molecular Genetics*, **2006**, 15, 1271-7	5.6	51
128	Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. *Cancer Research*, **2006**, 66, 10911-8	10.1	57
127	Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. *Human Molecular Genetics*, **2006**, 15, 2038-44	5.6	59
126	Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. *British Journal of Cancer*, **2006**, 95, 1288-90	8.7	21
125	. *IBM Systems Journal*, **2006**, 45, 647-655		2
124	Defining high-risk individuals in a population-based molecular-epidemiological study of lung cancer **2006**, 28, 1295		1
123	Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. *British Journal of Cancer*, **2006**, 94, 561-8	8.7	183
122	The Liverpool Statement 2005: Priorities for the European Union/United States Spiral Computed Tomography Collaborative Group. *Journal of Thoracic Oncology*, **2006**, 1, 497-498	8.9	19
121	The Liverpool Statement 2005: priorities for the European Union/United States spiral computed tomography collaborative group. *Journal of Thoracic Oncology*, **2006**, 1, 497-8	8.9	4
120	Methylation discriminators in NSCLC identified by a microarray based approach. *International Journal of Oncology*, **2005**, 27, 105-11	1	14
119	Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 15785-90	11.5	705
118	The Liverpool Lung Project research protocol. *International Journal of Oncology*, **2005**, 27, 1633-45	1	18
117	An investigation of the tylosis with oesophageal cancer (TOC) locus in Iranian patients with oesophageal squamous cell carcinoma. *International Journal of Oncology*, **2004**, 25, 389-95	1	8
116	Glycine-extended gastrin promotes the growth of lung cancer. *Cancer Research*, **2004**, 64, 196-201	10.1	23

115	Three different subsite classification systems for carcinomas in the proximity of the GEJ, but is it all one disease?. *Journal of Gastroenterology and Hepatology (Australia)*, **2004**, 19, 24-30	4	11
114	METH-2 silencing and promoter hypermethylation in NSCLC. *British Journal of Cancer*, **2004**, 91, 1149-54	8.7	51
113	S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. *British Journal of Cancer*, **2004**, 91, 1515-24	8.7	39
112	Novel microsatellite markers and single nucleotide polymorphisms refine the tylosis with oesophageal cancer (TOC) minimal region on 17q25 to 42.5 kb: sequencing does not identify the causative gene. *Human Genetics*, **2004**, 114, 534-40	6.3	31
111	Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. *Oral Oncology*, **2003**, 39, 115-29	4.4	31
110	Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. *Journal of Gastroenterology and Hepatology (Australia)*, **2003**, 18, 683-9	4	21
109	TP53 mutations in malignant and premalignant Barrett's esophagus. *Ecological Management and Restoration*, **2003**, 16, 83-9	3	33
108	Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. *Journal of Pathology*, **2003**, 200, 610-9	9.4	67
107	Physical and transcript map of the minimally deleted region III on 17p implicated in the early development of Barrett's oesophageal adenocarcinoma. *Oncogene*, **2003**, 22, 4134-42	9.2	5
106	Absence of mutations in the VHL gene but frequent loss of heterozygosity at 3p25-26 in non-small cell lung carcinomas. *Lung Cancer*, **2003**, 39, 273-7	5.9	20
105	E-26. Molecular markers in early detection. *Lung Cancer*, **2003**, 41, S33-S34	5.9	
104	Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 1008-11		187
103	Fluorescent microsatellite analysis in bronchial lavage as a potential diagnostic tool for lung cancer. *Methods in Molecular Medicine*, **2003**, 75, 251-62		
102	Sequencing of difficult templates containing poly(A/T) tracts: closure of sequence gaps. *BioTechniques*, **2002**, 33, 276, 278, 280	2.5	7
101	p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. *International Journal of Cancer*, **2002**, 101, 248-52	7.5	23
100	Characterization of a 500 kb region on 17q25 and the exclusion of candidate genes as the familial Tylosis Oesophageal Cancer (TOC) locus. *Oncogene*, **2002**, 21, 6395-402	9.2	33
99	Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. *British Journal of Cancer*, **2002**, 87, 1308-13	8.7	28
98	Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. *International Journal of Oncology*, **2002**, 21, 369-73	1	5

97	A comparative guide to gene prediction tools for the bioinformatics amateur. *International Journal of Oncology*, **2002**, 20, 697-705	1	2
96	The Liverpool Lung Project: a molecular epidemiological study of early lung cancer detection. *European Respiratory Journal*, **2002**, 20, 464-79	13.6	14
95	Tobacco money: up in smoke?. *Lancet, The*, **2002**, 360, 1979-80; author reply 1981	40	1
94	Expression profiling of primary non-small cell lung cancer for target identification. *Oncogene*, **2002**, 21, 7749-63	9.2	130
93	A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer. *Lung Cancer*, **2002**, 37, 143-6	5.9	19
92	Von Hippel-Lindau tumour suppressor gene is not involved in sporadic human breast cancer. *Tumor Biology*, **2001**, 22, 131-6	2.9	11
91	Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). *Journal of Pathology*, **2001**, 193, 55-65	9.4	22
90	Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. *Cancer Genetics and Cytogenetics*, **2001**, 126, 147-54		18
89	Molecular Biomarkers Workshop: a European Strategy for Developing Lung Cancer Molecular Diagnostics in High Risk Populations. *Lung Cancer*, **2001**, 31, 339-345	5.9	14
88	Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. *Cancer Research*, **2001**, 61, 1624-8	10.1	27
87	A new rare allele at the CGG repeat polymorphism in the first intron of human c-H-ras gene. *In Vivo*, **2001**, 15, 105-8	2.3	1
86	Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. *Investigative Ophthalmology and Visual Science*, **2001**, 42, 2472-7		23
85	Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status. *International Journal of Cancer*, **2000**, 89, 133-41	7.5	24
84	The Von Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas. *International Journal of Cancer*, **2000**, 88, 503-505	7.5	7
83	c-mos immunoreactivity is an indicator of good prognosis in lung cancer. *Histopathology*, **2000**, 37, 45-54	7.3	6
82	Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. *Oral Oncology*, **2000**, 36, 256-63	4.4	174
81	Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. *Oral Oncology*, **2000**, 36, 311-27	4.4	121
80	Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. *Oral Oncology*, **2000**, 36, 404-13	4.4	53

79	K-ras Point Mutation Detection in Lung Cancer: Comparison of Two Approaches to Somatic Mutation Detection Using ARMS Allele-specific Amplification. *Clinical Chemistry*, **2000**, 46, 1929-1938	5.5	63
78	Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs). *Molecular Medicine*, **2000**, 6, 208-237	6.2	34
77	Sensitivity and limitations of high throughput fluorescent microsatellite analysis for the detection of allelic imbalance: application in lung tumors. *International Journal of Oncology*, **2000**, 16, 5-14	1	5
76	Peptide amidating activity in human bronchoalveolar lavage fluid: relationship to lung cancer, inflammation and infection. *International Journal of Oncology*, **2000**, 16, 327-32	1	
75	Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease. *Lung Cancer*, **2000**, 28, 37-42	5.9	30
74	Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosis. *Lung Cancer*, **2000**, 28, 211-24	5.9	8
73	Histological and molecular mapping of adenocarcinoma of the oesophagus and gastroesophageal junction: loss of heterozygosity occurs in histologically normal epithelium in the oesophagus and stomach. *Oncology Reports*, **2000**, 7, 521-8	3.5	5
72	Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma. *Cancer*, **2000**, 89, 1933-45	6.4	8
71	The Von Hippel-Lindau (VHL) tumor-suppressor gene is not mutated in sporadic human colon adenocarcinomas **2000**, 88, 503		1
70	hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. *Cancer Research*, **2000**, 60, 4216-21	10.1	37
69	Telomerase activity in non-small cell lung carcinomas correlates with smoking status. *International Journal of Oncology*, **1999**, 15, 961-5	1	2
68	Fractional allele loss indicates distinct genetic populations in the development of squamous cell carcinoma of the head and neck (SCCHN). *Carcinogenesis*, **1999**, 20, 2219-28	4.6	21
67	The tylosis esophageal cancer (TOC) locus: more than just a familial cancer gene. *Ecological Management and Restoration*, **1999**, 12, 173-6	3	38
66	Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer. *Oncogene*, **1999**, 18, 987-93	9.2	31
65	LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. *Human Pathology*, **1999**, 30, 1508-14	3.7	50
64	Envoplakin, a possible candidate gene for focal NEPPK/esophageal cancer (TOC): the integration of genetic and physical maps of the TOC region on 17q25. *Genomics*, **1999**, 59, 234-42	4.3	29
63	Microsatellite instability and p53 mutations in hepatocellular carcinoma. *Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications*, **1999**, 2, 155-61		18
62	Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. *Cancer Research*, **1999**, 59, 2690-5	10.1	32

61	Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q. *Oncogene*, **1998**, 17, 2101-5	9.2	32
60	Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. *British Journal of Cancer*, **1998**, 78, 950-7	8.7	72
59	Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. *American Journal of Pathology*, **1998**, 153, 1749-65	5.8	92
58	The Knights of the Round Table hypothesis of tumour suppressor gene function--noble sacrifice or sexual dalliance: genes, including p53, BRCA1/2 and RB have evolved by horizontal and vertical transmission of mating factor genes and are involved in gametogenesis, implantation, development and tumourigenesis. *International Journal of Oncology*, **1998**, 12, 5-35	1	1
57	Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer **1998**, 247-261		
56	Synchronous oral carcinomas: independent or common clonal origin?. *Cancer Research*, **1998**, 58, 2003-6	10.1	73
55	p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. *British Journal of Cancer*, **1997**, 75, 1119-24	8.7	11
54	Oral tylosis: a re-appraisal. *Oral Oncology*, **1997**, 33, 55-7	4.4	5
53	An immunohistochemical analysis of p53 protein expression in pre-malignant and malignant tissues of the oral cavity. *Clinical Otolaryngology*, **1997**, 22, 23-9		10
52	p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck. *International Journal of Cancer*, **1997**, 71, 796-9	7.5	22
51	p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. *Cancer Research*, **1997**, 57, 4070-4	10.1	33
50	Molecular basis of familial cleft lip and palate. *Oral Diseases*, **1996**, 2, 238-41	3.5	12
49	Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck. *International Journal of Cancer*, **1996**, 66, 464-9	7.5	93
48	Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. *British Journal of Cancer*, **1996**, 74, 1968-74	8.7	28
47	Close mapping of the focal non-epidermolytic palmoplantar keratoderma (PPK) locus associated with oesophageal cancer (TOC). *Human Molecular Genetics*, **1996**, 5, 857-60	5.6	37
46	Genomic instability in head and neck cancer. *Current Topics in Pathology Ergebnisse Der Pathologie*, **1996**, 90, 201-22		6
45	Genomic instability in squamous cell carcinoma of the head and neck. *Anticancer Research*, **1996**, 16, 2421-31	1.3	29
44	Microsatellite instability in squamous cell carcinoma of the head and neck. *British Journal of Cancer*, **1995**, 71, 1065-9	8.7	77

43	Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. *British Journal of Cancer*, **1995**, 72, 123-8	8.7	76
42	The treatment of node negative squamous cell carcinoma of the postcricoid region. *Journal of Laryngology and Otology*, **1995**, 109, 114-9	1.8	4
41	Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. *Clinical Otolaryngology*, **1995**, 20, 266-71	1.8	20
40	Second primary tumors in patients with head and neck squamous cell carcinoma. *Cancer*, **1995**, 75, 1343-53	5.4	272
39	Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. *British Journal of Cancer*, **1995**, 71, 995-8	8.7	24
38	Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. *British Journal of Cancer*, **1995**, 72, 1180-8	8.7	100
37	Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. *Oncogene*, **1995**, 11, 581-5	9.2	30
36	The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. *Journal of the Royal Society of Medicine*, **1995**, 88, 35P-39P	2.3	4
35	The detection of the c-myc and ras oncogenes in nasopharyngeal carcinoma by immunohistochemistry. *Acta Oto-Laryngologica*, **1994**, 114, 105-9	1.6	46
34	Tylosis oesophageal cancer mapped. *Nature Genetics*, **1994**, 8, 319-21	36.3	62
33	Tylosis associated with carcinoma of the oesophagus and oral leukoplakia in a large Liverpool family--a review of six generations. *European Journal of Cancer Part B, Oral Oncology*, **1994**, 30B, 102-12		65
32	Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. *Journal of Laryngology and Otology*, **1994**, 108, 957-61	1.8	9
31	The treatment of early squamous cell carcinoma of the piriform fossa. *Clinical Otolaryngology*, **1994** , 19, 485-90	1.8	7
30	The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. *Clinical Otolaryngology*, **1994**, 19, 63-9	1.8	79
29	Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. *Oncogene*, **1994**, 9, 2077-82	9.2	43
28	Expression of the cell-cell adhesion molecule E-cadherin in squamous cell carcinoma of the head and neck. *Clinical Otolaryngology*, **1993**, 18, 196-201		45
27	Exposure to cigarette smoke and expression of the protein encoded by the p53 gene in bronchial carcinoma. *Annals of the New York Academy of Sciences*, **1993**, 686, 243-7; discussion 247-8	6.5	6
26	The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. *JAMA Otolaryngology*, **1993**, 119, 1118-22		98

25	Non-squamous malignancy in lymph nodes: the occult primary. *Clinical Otolaryngology*, **1993**, 18, 311-6	1.8	5
24	Prognostic significance of oncogenes and tumor suppressor genes in human malignancy. *Stem Cells* , **1993**, 11, 194-8	5.8	4
23	Epigenetic silencing of the endothelin-B receptor gene in non-small cell lung cancer **1992**, 34, 465		
22	A phase II study of cisplatinum versus cisplatinum + nifedipine in end-stage carcinoma of the head and neck. *Clinical Otolaryngology*, **1992**, 17, 501-4	1.8	4
21	Multiple cytogenetic aberrations in squamous cell carcinomas of the head and neck. *European Journal of Cancer Part B, Oral Oncology*, **1992**, 28B, 17-21		23
20	Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. *Lancet, The*, **1992**, 339, 502-3	40	69
19	Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. *European Journal of Cancer Part B, Oral Oncology*, **1992**, 28B, 67-76		125
18	C-erbB-2 expression in squamous cell carcinoma of the head and neck. *Anticancer Research*, **1992**, 12, 613-9	2.3	35
17	Low levels of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma. *European Journal of Surgical Oncology*, **1992**, 18, 168-76	3.6	11
16	Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. *British Journal of Cancer*, **1991**, 64, 573-7	8.7	230
15	Immunohistochemical analysis of the expression of the c-myc oncoprotein in human stomach cancers. *Digestion*, **1991**, 50, 127-34	3.6	7
14	Prognostic Implications of ras Oncogene Expression in Head and Neck Squamous Cell Carcinoma **1991**, 213-226		2
13	Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung. *Anticancer Research*, **1990**, 10, 1105-14	2.3	13
12	The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). *Anticancer Research*, **1990**, 10, 1-22	2.3	125
11	Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. *Oncogene*, **1989**, 4, 1463-8	9.2	90
10	Time, steam, temperature (TST) control indicators to measure essential sterilisation criteria for autoclaves in general dental practice and the community dental service. *British Dental Journal*, **1988** , 164, 183-6	1.2	2
9	A physical and microbiological evaluation of the re-use of non-sterile gloves. *British Dental Journal*, **1988**, 165, 321-4	1.2	20
8	Expression of oncogenes in human tumours with special reference to the head and neck region. *Journal of Oral Pathology and Medicine*, **1987**, 16, 97-107	3.3	38

7	Clinical relevance of oncogene expression in head and neck tumours. *Anticancer Research*, **1986**, 6, 595-600	2.9	31
6	Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. *Anticancer Research*, **1985**, 5, 221-4	2.3	70
5	Sex differences in sexual needs and desires. *Archives of Sexual Behavior*, **1984**, 13, 233-45	3.5	76
4	A microcomputer program for analysis of nucleic acid hybridization data. *Nucleic Acids Research*, **1982**, 10, 1411-20	20.1	15
3	EFFECTS OF OESTROGENS ON THE COMPLEXITY OF POLY (A) RNA FROM RAT UTERUS. *Biochemical Society Transactions*, **1981**, 9, 153P-153P	5.1	
2	The response to hormones and anti-hormones of human breast tumour cells grown in continuous culture [proceedings]. *Biochemical Society Transactions*, **1978**, 6, 1318-9	5.1	
1	A further study of the inheritance of racing performance in thoroughbred horses. *Journal of Heredity*, **1976**, 67, 247-8	2.4	11